• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

News

Article

September 18, 2023

Analysis Indicates Highly Cited COVID-19 Research is Trending Downwards Compared to Early in Pandemic

Author(s):

Gillian McGovern, Associate Editor

Research shows a peak of highly cited COVID-19 studies at the end of 2021 and a significant downward trend by the end of 2022.

In response to the COVID-19 outbreak at the end of 2019, various research has been conducted worldwide to better understand the virus. Constantly evolving, the number of COVID-19-related publications now surpasses 350,000 studies; however, the COVID-19 pandemic has also been associated with an increased amount of waste studies that are poorly designed or conduct unnecessary research, according to the authors of a recent study published in JAMA Network Open.

Health care professional performing a nasal COVID-19 test on a patient

Image credit: Prostock-studio | stock.adobe.com

The cross-sectional study examined prior (in the past 2 months) highly cited studies on COVID-19 to investigate research trends by conducting a bibliometric analysis. Essential Science Indicators (ESI) and Web of Science (WOS) Core Collection were used to find studies with a focus on COVID-19 that were identified as highly cited studies from Clarivate Analytics.

Studies were identified based on 5 selection steps: the authors extracted a total of 18 periods of highly cited studies from the ESI database bimonthly from January 2020 to December 2022; accession number; key words in the titles and abstracts; the number of researchers involved; and the same 4 researchers checked how many duplicates were counted between each period. Research that included keywords related to COVID-19 (e.g., “COVID-19” “coronavirus disease 2019” “SARS-CoV-2” “2019-nCoV”) in the text but did not investigate the virus were excluded from the analysis. To measure the trend of COVID-19-related research, the study authors used 3 different variables when assessing the research: the research fields variable (included 22 ESI categories [e.g., agricultural science, biology and biochemistry, clinical medicine, immunology]), the countries variable (countries of affiliation of all co-authors), and the affiliations variable (affiliations of all co-authors).

The study’s findings indicate that as the pandemic progressed, the number of highly cited studies focused on COVID-19 had significantly increased; however, after hitting a peak of 1292 at the end of 2021, the number of studies performed had begun to trend downward, reaching 649 studies from November to December 2022. Initially, China had the highest number of highly cited studies per 2-month period (138.3 studies), but the number had shifted, with the Unite States (159.9 studies) surpassing China (157.6 studies) per 2-month period in September to October 2020. Initially, most highly cited studies were in the clinical medicine field, but there was an increase in the number of publications from different fields during the observational period.

The number of studies published by China had declined significantly, decreasing from 179.7 studies in November to December 2020 to 40.7 studies by September to October 2022. Further, the top.5 institutional affiliations in May to June 2020 by highly cited studies per 2-month period were from China (Huazhong University: 14.7 studies; University of Hong Kong: 6.8 studies; Wuhan University: 4.8 studies; Zhejiang University: 4.5 studies; Fudan University: 4.5 studies), whereas in November to December 2022, the top 5 institutions were from the United States and United Kingdom (Harvard University: 15.0 studies; University College London: 11.0 studies; University of Oxford: 10.2 studies; University of London: 9.9 studies; Imperial College London: 5.8 studies).

The authors note that like the current study, a prior analysis had found the United States steadily increased in the number of studies, passing China who initially led COVID-19 research. Further, this study found that the UK had showed the opposite trend and started with a slow pace of publications until gradually increasing its contributions as the year progressed. Additionally, another study had examined the association of publications centered around COVID-19 with overall publication rates in high-impact factor journals and found that COVID-19 studies had accounted for approximately 10% to 50% of the total number of publications in each high-impact journal from 2020 to 2021, with a gradual decline observed at the end of 2020.

Another study had reported that an increase in COVID-19 cases in a region or country was associated with an increase in research activity focused on COVID-19. The authors believe that the association is due to the need for data and increased government funding in COVID-19 research to gain control over the pandemic.

The current study’s findings of gradual downward trends in highly cited COVID-19 studies may also be associated with a decrease in attention to COVID-19 research, suggesting that investigators have better knowledge of the etiology and treatment of COVID-19. Changes in distribution, top affiliations, and research fields of highly cited studies suggest there is a gradual shift in interest in COVID-19 research toward more diversified and broader research areas. In the future, the current study authors predict there will be a sustained reduction in the number of highly cited studies on COVID-19.

Limitations of the study include the wide use of fractional counting making it difficult to properly compare results with other research, the limitation of using the top 0.1% of citations that is not an accurate representation of all published literature, and the use of ESI categories to define research fields that do not classify highly cited studies in detail. Additionally, the study provided a broad overview of identified trends in COVID-19-related highly cited studies, rather than a detailed analysis, according to the authors.

Reference

Funada S, Yoshioka T, Luo Y, et al. Global Trends in Highly Cited Studies in COVID-19 Research. JAMA Netw Open. 2023;6(9):e2332802. doi:10.1001/jamanetworkopen.2023.32802

Related Videos
Image credit: Dr_Microbe | stock.adobe.com
Image credit: K KStock | stock.adobe.com
Image credit: komokvm | stock.adobe.com
Vial of Pneumococcal vaccine - Image credit: Bernard Chantal | stock.adobe.com
Related Content
Advertisement
NLA 2025: Data on ApoC3 Inhibitors Shows Promise Across a Spectrum of Hypertriglyceridemic Disorders
May 31st 2025

NLA 2025: Data on ApoC3 Inhibitors Shows Promise Across a Spectrum of Hypertriglyceridemic Disorders

Alana Hippensteele, Lead Editor
Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings
May 28th 2025

Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings

Alexandra Gerlach, Associate Editor
Illustration of myocardial infarction
May 30th 2025

NLA 2025: Inclisiran With Standard Care Provides Rapid, Sustained Lowering of LDL-C in Patients With Recent Acute Coronary Syndrome

Luke Halpern, Assistant Editor
Pharmacy Focus: Navigating Seasonal Allergies
May 28th 2025

Pharmacy Focus: Navigating Seasonal Allergies

Luke Halpern, Assistant Editor Derek Webb, PharmD
Woman can't eat bread and grain products because of gluten intolerance. A young celiac woman suffers from abdominal pain after eating fresh bread - Image credit: weyo | stock.adobe.com
May 30th 2025

FDA Grants Fast Track Designation to Drug Candidate for Celiac Disease

Kennedy Ferruggia, Assistant Editor
Washington, DC, USA - June 24, 2022: The symbol of the U.S. Department of Health and Human Services is seen at the entrance to its headquarters in the Hubert H. Humphrey Building in Washington, DC
May 30th 2025

HHS Cancels Millions in Pandemic Influenza mRNA Vaccine Development Grants

Luke Halpern, Assistant Editor
Related Content
Advertisement
NLA 2025: Data on ApoC3 Inhibitors Shows Promise Across a Spectrum of Hypertriglyceridemic Disorders
May 31st 2025

NLA 2025: Data on ApoC3 Inhibitors Shows Promise Across a Spectrum of Hypertriglyceridemic Disorders

Alana Hippensteele, Lead Editor
Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings
May 28th 2025

Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings

Alexandra Gerlach, Associate Editor
Illustration of myocardial infarction
May 30th 2025

NLA 2025: Inclisiran With Standard Care Provides Rapid, Sustained Lowering of LDL-C in Patients With Recent Acute Coronary Syndrome

Luke Halpern, Assistant Editor
Pharmacy Focus: Navigating Seasonal Allergies
May 28th 2025

Pharmacy Focus: Navigating Seasonal Allergies

Luke Halpern, Assistant Editor Derek Webb, PharmD
Woman can't eat bread and grain products because of gluten intolerance. A young celiac woman suffers from abdominal pain after eating fresh bread - Image credit: weyo | stock.adobe.com
May 30th 2025

FDA Grants Fast Track Designation to Drug Candidate for Celiac Disease

Kennedy Ferruggia, Assistant Editor
Washington, DC, USA - June 24, 2022: The symbol of the U.S. Department of Health and Human Services is seen at the entrance to its headquarters in the Hubert H. Humphrey Building in Washington, DC
May 30th 2025

HHS Cancels Millions in Pandemic Influenza mRNA Vaccine Development Grants

Luke Halpern, Assistant Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

Download on Apple
© 2025 MJH Life Sciences

All rights reserved.